1 |
Grzesiak, A.L., Matzger, A.J., 2007. Selection and discovery of polymorphs of platinum complexes facilitated by polymerinduced heteronucleation. Inorg. Chem. 46, 453-457.
DOI
|
2 |
Grzesiak, A.L., Uribe, F.J., Ockwig, N.W., Yaghi, O.M.,Matzger, A.J., 2006. Polymer-induced heteronucleation for the discovery of new extended solids. Angew. Chem. Int. Edit 45, 2553-2556.
DOI
|
3 |
Lang, M., Grzesiak, A.L., Matzger, A.J., 2002. The use of polymer heteronuclei for crystalline polymorph selection. J. Am. Chem. Soc. 124, 14834-14835.
DOI
|
4 |
Price, C.P., Grzesiak, A.L., Kampf, J.W., Matzger, A.J., 2003. Maize 1: A trimorphic azo pigment. Cryst. Growth Des. 3, 1021-1025.
DOI
|
5 |
Price, C.P., Grzesiak, A.L., Lang, M., Matzger, A.J., 2002. Polymorphism of abumetone. Cryst. Growth Des. 2, 501-503.
DOI
|
6 |
Price, C.P., Grzesiak, A.L., Matzger, A.J., 2005. Crystalline polymorph selection and discovery with polymer heteronuclei. J. Am. Chem. Soc. 127, 5512-5517.
DOI
|
7 |
Rodriguez-Spong, B., Price, C.P., Jayasankar, A., Matzger, A.J., Rodriguez-Hornedo, N., 2004. Generalprinciples of pharmaceutical solid polymorphism: A supramolecular perspective. Adv. Drug Delivery Rev. 56, 241-274.
DOI
|
8 |
Tiwary, A.K., 2001. Modification of crystal habit and its role in dosage form performance. Drug Dev. Ind. Pharm. 27, 699-709.
DOI
|
9 |
Brittain, H.G., Grant, D.J.W., 1999. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In: Swarbrick, J. (Ed.), Polymorphism in Pharmaceutical Solids. Marcel Dekker, New York, pp. 279-330.
|
10 |
Adam, L.G., Adam, J. M., 2007. New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymerinduced heteronucleation. J. Pharm. Sci. 96, 2978-2986.
DOI
|
11 |
Chao, R.S., Vail, K.C., 1987. Polymorphism of 1,2-dihydro-6-neopentyl-2-oxonicotinic acid: characterization, interconversion, and quantitation. Pharm. Res. 4, 429-432.
DOI
|